Trial Profile
A Phase 1/2a Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression Who Have Failed Standard Available Therapy
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 May 2023
Price :
$35
*
At a glance
- Drugs HPN 536 (Primary)
- Indications Carcinoma; Malignant-mesothelioma; Mesothelioma; Ovarian cancer; Pancreatic cancer; Peritoneal cancer
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Harpoon Therapeutics
- 03 May 2023 Status changed from active, no longer recruiting to completed.
- 09 Sep 2022 Status changed from recruiting to active, no longer recruiting.
- 04 Apr 2022 Planned number of patients changed from 180 to 200.